Professor at the University of Granada. Director of the Research Group consolidated by the Ministry of Education of the Junta de Andalucía CTS-101: Intercellular; Director of MP17- Comunicación Intercelular (IBS of Granada); and Director of the group CB16/10/00238 of CIBERfes, the CIBER on frailty and aging. Supervisor of Radioactive Installations. I am also a specialist in Clinical Biochemistry. I have developed my research for the last 30 years in the Department of Physiology of the Faculty of Medicine at the University of Granada. Research interest: Inflammation, melatonin, mitochondrial bioenergetics, oxidative stress, mitochondrial diseases, cancer, chemoresistance, metastasis, sepsis. Research achievements: I have four international patents on melatonin in the last years: (PCT/ES2012/070728), (PCT/ES2012/070349 and PCT/ES2015/070236) have been licensed to Pharmamel S.L, the

Spin-Off created by us through the University of Granada and are under clinical trials. These are patented as a prescription drugs: the former for the prevention and healing of oral mucositis induced by radio and/or chemotherapy, and the other two for its endovenous administration against sepsis. The fourth patent (PCT/ES2013/070817), also licensed to Pharmamel S.L., consists in a regenerative and anti-aging cream for topic application in the skin. A clinical trial with this cream to treat position ulcers and to treat radiodermitis, are now being carry out in collaboration with to other groups of CIBERFes (ISCIII) and hospitals, respectively. A last patent is PCT/ES2020/070234, “Composición inyectable de melatonina para el tratamiento de enfermedades virales”. Published key articles on the effects of melatonin on the mitochondrial respiratory chain and ATP synthesis, showing that they are the main target of melatonin in the cell; Extensive reports on the antioxidative, anti-inflammatory and neuroprotective effects of melatonin; Extensive reports on the antioxidative, anti-inflammatory and effects of melatonin to prevent adverse effects of chemo and radiotherapy such as mucositis; Published key articles on the dual effects of melatonin to protect normal cells and kill cancer cells. -I have developed two Phase II trials with melatonin in sepsis (EudraCT: 2008-006782-83) and covid-19 (EudraCT 2020-001808-42). The results led us to currently preparing a Phase III trial in sepsis. I am cofounder of two companies, Pharmamel Dermo SL and Pharmamel Drug Discovery SA. I have published over 300 publications including articles, proceedings and book chapters, and over 50 oral presentations at international meetings. I am an Associate Editor of the Journal of pineal Research (IF: 10,3) and referee for several international magazines. In addition, I maintain collaborations with various Universities: University of San Antonio (Texas, USA) with Professor Russel J Reiter; Pontificia Universidad Católica Argentina, with Prof. Daniel P Cardinali and Agata Carpentieri; Institute of Neuroscience of the University of Antioquia (Colombia) with Professor Marlene Jiménez, being Dra Escames international advisor for research projects; Mayo Clinic (USA) with Prof. Quiñones, Dr Felix Oppel from Bielefeld (Germany), Prof. Kuebler from Berlin (Germany) and Prof Vandier from Tours (France), as well as with various Spanish Universities General quality indicators of scientific production -Number six-year terms = 5; Last granted in: 2025 -Number of six-year transfer = 1 granted in 2020 -Number of Doctoral Theses supervised in the last 10 years = 29 -Data obtained from the Bibliometrics Unit of the University of Granada through Google Scholar -Total citations = 15624; in the last 5 years = 6611; total articles in the first quartile (Q1) = 90; h index = 72;